Venus Concept

Venus Concept, Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related practice enhancement services. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Venus Concept surpasses revenue expectations in Q1 2024 earnings call

Venus Concept's Q1 2024 performance showed resilience with revenue exceeding expectations despite challenges. Strategic initiatives to exit unprofitable markets and focus on cash system sales led to improved financial metrics. The company's progress in key initiatives and financial improvements demonstrate a commitment to long-term growth and stability.

Venus Concept reports mixed Q3 results, eyes growth opportunities

Venus Concept faced revenue challenges in Q3 2024, but saw growth in distributor sales and progress in restructuring efforts. Despite financial setbacks, the company is optimistic about new product launches, regulatory clearances, and debt reduction strategies. Analyst interest remains high in revenue mix, new product launches, market strengths, and debt management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

TORONTO, March 25, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO) announced today that it received a decision from the Nasdaq Hearings Panel (the “Nasdaq Panel”) granting its request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) or any of the alternative requirements under Nasdaq Listing Rule 5550(b) on or before May 28, 2024, and certain other conditions (the “Panel Decision”).

Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules

New Venus AI Event Series Focused on Enhancing Customer Education and Training New Venus AI Event Series Focused on Enhancing Customer Education and Training

Venus Concept Launches “NEXThetics” Program

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 817,748 shares of common stock at a purchase price of $1.465 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 817,748 shares of common stock at an exercise price of $1.34 per share that are immediately exercisable upon issuance and will expire five years following the date of issuance.

Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TORONTO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 817,748 shares of common stock at a purchase price of $1.465 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 817,748 shares of common stock at an exercise price of $1.34 per share that will be immediately exercisable upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about February 27, 2024, subject to the satisfaction of customary closing conditions.

Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received the CE Mark from DEKRA Certification B.V. to market the Venus Versa Pro system in the European Union. This follows the Company's announcement on November 1, 2023 regarding the commercial launch of the device in the United States.

Venus Concept Announces CE Mark for Venus Versa Pro in Europe

TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2023 financial results will be released before the market opens on Monday, April 1, 2024.

Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024

TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that its Board of Directors (the “Board”) is evaluating potential strategic alternatives to maximize shareholder value. As part of the process, the Board is considering a full range of strategic alternatives, which may include one or more financings, mergers, reverse mergers, other business combinations, sales of assets, licensings or other transactions.

Venus Concept Inc. Announces Review of Strategic Alternatives

Sale of convertible notes provides additional financial flexibility and support for the Company's path to cash flow breakeven Sale of convertible notes provides additional financial flexibility and support for the Company's path to cash flow breakeven

Venus Concept Inc. Announces Issuance of $2.0M of Convertible Notes

TORONTO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the launch of Venus Prime, a structured in-house financing program replacing its legacy subscription program for new customers in North America. Under our Venus Prime program, select customers can qualify for competitive financing rates and continue to benefit from the payment flexibility afforded by our previous subscription financing program when purchasing our aesthetic medical devices, as well as a seamless technology upgrade program made available to our customers in years 2 and 3 of ownership. Venus Prime is now available to qualifying customers who may not currently be eligible for financing by traditional third-party lenders under current tight lending practices but demonstrate reputable credit and business practices.

Venus Concept Launches Venus Prime

Venus Concept (VERO) expects its deals to fetch continued success in both the United Kingdom and India.

Venus Concept (VERO) Expands Global Reach With New Partnerships

TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced the expansion of its international distributor network with the signing of two new exclusive partnerships: Core Aesthetics Skin & Laser Limited (“Core Aesthetics”) in the United Kingdom and Spectra Medical Systems (“Spectra”) in India. Both regions are high growth markets for the Company. The execution of these agreements represents an important step towards Venus Concept's focus of driving international growth through strong distributor partnerships.

Venus Concept Announces New International Distributors in the United Kingdom and India to Continue Global Growth

Venus Concept Inc. (NASDAQ:VERO ) Q3 2023 Earnings Conference Call November 14, 2023 5:00 PM ET Company Participants Rajiv De Silva - Chief Executive Officer Hemanth Varghese - President & Chief Operating Officer Domenic Della Penna - Chief Financial Officer Conference Call Participants Jeff Cohen - Ladenburg Thalmann Sam Eiber - BTIG Operator Please standby. Good day, ladies and gentlemen.

Venus Concept Inc. (VERO) Q3 2023 Earnings Call Transcript

TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2023.

Venus Concept Announces Third Quarter of Fiscal Year 2023 Financial Results

TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the commercial launch of its new multi-application platform Venus Versa Pro in the United States.

Venus Concept Launches Venus Versa Pro, its new multi-application platform for face and body treatments

TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today a company-wide rebranding initiative, introducing Venus Aesthetic Intelligence (or "Venus AI") to reflect its new strategic vision for the company and an enhanced focus on emerging technologies in aesthetics.

Venus Concept Launches New “Venus Aesthetic Intelligence” Branding and Updated “Venus.ai” Website to Reflect New Vision for the Company

TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer.

Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

TORONTO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2023 financial results will be released after the market closes on Tuesday, November 14, 2023.

Venus Concept to Release Third Quarter of Fiscal Year 2023 Financial Results on November 14, 2023

Provides significant financial flexibility and support for the Company's path to cash flow breakeven by reducing total debt, deferring principal and interest payments, and lowering near-term cash needs Provides significant financial flexibility and support for the Company's path to cash flow breakeven by reducing total debt, deferring principal and interest payments, and lowering near-term cash needs

Venus Concept Inc. Announces Debt Restructuring, Preliminary Third Quarter 2023 Revenue Results and Updates Fiscal Year 2023 Revenue Guidance

TORONTO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its Venus Versa Pro System, the Company's new multi-application platform, for a variety of aesthetic and cosmetic procedures.

Venus Concept Receives 510(k) Clearance for the Venus Versa Pro System, Its New Multi-Application Platform

TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference, which is being held virtually and in person at the Lotte New York Palace in New York, NY from September 11th-13th.

Venus Concept Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Venus Concept Inc. (NASDAQ:VERO ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Company Participants Rajiv De Silva – Chief Executive Officer Hemanth Varghese – President and Chief Innovation and Business Officer Domenic Della Penna – Chief Financial Officer Conference Call Participants Jeff Cohen – Ladenburg Thalmann Marie Thibault – BTIG Anthony Vendetti – Maxim Group Operator Good day, ladies and gentlemen. Welcome to the Second Quarter 2023 Earnings Conference Call for Venus Concept.

Venus Concept Inc. (VERO) Q2 2023 Earnings Call Transcript

TORONTO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2023.

Venus Concept Announces Second Quarter of Fiscal Year 2023 Financial Results

TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the establishment of a medical advisory board for AI.ME, its next generation robotic platform.

Venus Concept Announces Establishment of Medical Advisory Board For AI.ME™ -Its Next Generation Robotic Platform

TORONTO, July 05, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2023 financial results will be released after the market closes on Monday, August 14, 2023.

Venus Concept to Release Second Quarter of Fiscal Year 2023 Financial Results on August 14, 2023

Venus Concept Inc. (NASDAQ:VERO ) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET Company Participants Rajiv De Silva - CEO Hemanth Varghese - President & Chief Innovation and Business Officer Domenic Della Penna - CFO Conference Call Participants Destiny Hance - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2023 Earnings Conference Call for Venus Concept Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay.

News for Venus Concept Stock (VERO)